Haby Henary
About
Haby Henary is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Haby Henary has authored 32 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Haby Henary's work include Colorectal Cancer Treatments and Studies (12 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Genomics and Diagnostics (6 papers). Haby Henary is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Genomics and Diagnostics (6 papers). Haby Henary collaborates with scholars based in United States, Australia and United Kingdom. Haby Henary's co-authors include Erik Rasmussen, David S. Hong, Gerald S. Falchook, Ramaswamy Govindan, Marwan Fakih, Jayesh Desai, Timothy Price, James Kuo, Jude Ngang and Phuong K. Morrow and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.
In The Last Decade
Haby Henary
32 papers receiving 696 citations
Peers
Haby Henary
Raymond Wadlow United States
P.N. Munster United States
Nicoletta Staropoli Italy
Karen A. Cadoo United States
Shane K. Green Canada
Santai Song China
Elisabeth Llonch Switzerland
Nicoletta Cordani Italy
Sharon Friedlander United States
Giuseppe Gullo Ireland
Citations per year, relative to Haby Henary Haby Henary (= 1×)
peers
Raymond Wadlow
Countries citing papers authored by Haby Henary
Since
Specialization
Citations
This map shows the geographic impact of Haby Henary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haby Henary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haby Henary more than expected).
Fields of papers citing papers by Haby Henary
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Haby Henary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haby Henary. The network helps show where Haby Henary may publish in the future.
Co-authorship network of co-authors of Haby Henary
This figure shows the co-authorship network connecting the top 25 collaborators of Haby Henary. A scholar is included among the top collaborators of Haby Henary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haby Henary. Haby Henary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kulasekararaj, Austin, Francesco Lanza, Saskia Langemeijer, et al.. (2024). Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology. 99(11). 2108–2117.
2.
Kulasekararaj, Austin, et al.. (2023). Efficacy of Parallel and Crossover Analysis As Well As Pharmacokinetic Similarity Were Confirmed between ABP 959 and Eculizumab Reference Product in Patients with PNH. Blood. 142(Supplement 1). 4092–4092.
3.
Moschos, Stergios J., Shahneen Sandhu, Karl D. Lewis, et al.. (2022). Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. Investigational New Drugs. 40(5). 1051–1065.
4.
Fakih, Marwan, Greg Andrew Durm, Ramaswamy Govindan, et al.. (2021). MO01.30 Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101). Journal of Thoracic Oncology. 16(1). S28–S28.
5.
Skoulidis, Ferdinandos, Gerald S. Falchook, Adrian G. Sacher, et al.. (2021). PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis. Journal of Thoracic Oncology. 16(3). S61–S61.
6.
Strickler, John H., Marwan Fakih, Jayesh Desai, et al.. (2020). SO-24 AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial. Annals of Oncology. 31. S226–S226.
7.
Strickler, John H., Marwan Fakih, Timothy Price, et al.. (2020). 83MO AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial. Annals of Oncology. 31. S1274–S1275.
8.
Hong, David S., James Kuo, Adrian G. Sacher, et al.. (2020). CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).. Journal of Clinical Oncology. 38(15_suppl). 3511–3511.
9.
Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). OA01.06 Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(11). S1125–S1126.
10.
Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. Journal of Thoracic Oncology. 14(10). S208–S208.
11.
Rosenthal, Mark, Richard Curry, David A. Reardon, et al.. (2019). Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemotherapy and Pharmacology. 84(2). 327–336.
12.
Massard, Christophe, Jean‐Charles Soria, Jürgen Krauß, et al.. (2019). First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 83(6). 1057–1063.
13.
Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(11). S1191–S1192.
14.
Langenberg, Marlies H.G., Vincent A. de Weger, Robert Frank, et al.. (2016). A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma. European Journal of Cancer. 69. S34–S34.
15.
Henary, Haby, Goldy C. George, Jennifer J. Wheler, et al.. (2015). A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 76(3). 597–603.
16.
Hong, David S., Haby Henary, G. S. Falchook, et al.. (2014). First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. Investigational New Drugs. 32(6). 1204–1212.
17.
Henary, Haby, David S. Hong, G. S. Falchook, et al.. (2013). Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Annals of Oncology. 24(8). 2158–2165.
18.
Amato, Robert J., Joan Hernandez-McClain, & Haby Henary. (2008). Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate. Urologic Oncology Seminars and Original Investigations. 27(1). 8–13.
19.
Amato, Robert J., Joan Hernandez-McClain, & Haby Henary. (2008). Bone-Targeted Therapy. American Journal of Clinical Oncology. 31(6). 532–538.
20.
Amato, Robert J., et al.. (2008). A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urologic Oncology Seminars and Original Investigations. 27(2). 165–169.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Raymond Wadlow Breakdown of academic impact, for papers by P.N. Munster Breakdown of academic impact, for papers by Nicoletta Staropoli Breakdown of academic impact, for papers by Karen A. Cadoo Breakdown of academic impact, for papers by Shane K. Green Breakdown of academic impact, for papers by Santai Song Breakdown of academic impact, for papers by Elisabeth Llonch Breakdown of academic impact, for papers by Nicoletta Cordani Breakdown of academic impact, for papers by Sharon Friedlander Breakdown of academic impact, for papers by Giuseppe Gullo